Showing 601 - 620 results of 2,809 for search 'Khaas~', query time: 3.52s Refine Results
  1. 601

    Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation by Stephen E. Langabeer, Stuart Macleod, Úna Bhreathnach, Kamal Fadalla

    Published 2023-01-01
    “…Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). …”
    Get full text
    Article
  2. 602
  3. 603

    Assessment of microbial diversity and antimicrobial resistance in raw camel milk: Genomic and phenotypic analysis of Kharai and Kutchi breeds of Gujarat, India by Hetvi J. Adhyaru, Devangi B. Mangroliya, Jayesh H. Kabariya, Vimal M. Ramani

    Published 2025-03-01
    “…Both breeds exhibit unique microbial compositions, with the Kharai breed having a more diverse bacterial community. …”
    Get full text
    Article
  4. 604
  5. 605
  6. 606
  7. 607

    Variation in the Lipid Profile of Pacific Oyster ( Crassostrea gigas ) Cultured in Khanh Hoa Coast, Vietnam, Based on Location and Harvest Period by Minh Van Nguyen, Derrick Kakooza, Anh Phuong Thi Tran, Vy Thao Thi Tran

    Published 2024-01-01
    “…The lipid profiles of the oyster Crassostrea gigas cultured in Khanh Hoa coast at three locations and harvested in different months throughout the year were compared. …”
    Get full text
    Article
  8. 608

    Aurora kinase B inhibitor AZD1152: repurposing for treatment of lupus nephritis driven by the results of clinical trialsResearch in context by Yue Zhao, Zuguo Zheng, Xuexiao Jin, Shaoshan Liang, Changming Zhang, Mingchao Zhang, Yue Lang, Ping Li, Zhihong Liu

    Published 2025-02-01
    “…Methods: AZD1152, an Aurora kinase B (Aurkb) inhibitor, was identified through transcriptomic analyses and the L1000 CMap drug repurposing database. …”
    Get full text
    Article
  9. 609
  10. 610

    Silent Neuroleptic Malignant Syndrome: A Case Report of Atypical Antipsychotic Induced Elevation of Creatinine Kinase and Altered Mental Status by Amber N. Edinoff, Hamza Mohammad-Amin, Amira S. Odisho

    Published 2022-08-01
    “…Two days after medication initiation, the patient's mentation was altered and he appeared confused with an elevated creatine kinase (CK) at 7101. Medications were held and CK normalized with IV fluids. …”
    Get full text
    Article
  11. 611

    A Novel Analytical Inverse Kinematics Method for SSRMS-Type Space Manipulators Based on the POE Formula and the Paden-Kahan Subproblem by Yecong Wang, Xilun Ding, Zixin Tang, Chengwei Hu, Qingqing Wei, Kun Xu

    Published 2021-01-01
    “…Although widely used in establishing the kinematics of SSRMS-type manipulators, the Denavit-Hartenberg (DH) method has a singular problem when two adjacent joint axes are nearly parallel. …”
    Get full text
    Article
  12. 612
  13. 613
  14. 614
  15. 615
  16. 616

    Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis. by Konstantinos Ouranos, Diana V Avila, Evangelia K Mylona, Athanasios Vassilopoulos, Stephanos Vassilopoulos, Fadi Shehadeh, Eleftherios Mylonakis

    Published 2024-01-01
    “…The goal of our study was to calculate the pooled cumulative incidence and risk of infection in patients with RA treated with Janus kinase inhibitors (JAKi). The PubMed and EMBASE databases were queried for randomized controlled trials comparing patients with RA treated with JAKi (upadacitinib, baricitinib, tofacitinib, peficitinib, or filgotinib), defined as the treatment group, compared with control subjects, defined as participants receiving placebo or treatment regimen that was similar to that of participants in the treatment group, with the exception of JAKi. …”
    Get full text
    Article
  17. 617

    Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future? by Beatrice Maranini, Roberta Foti, Moustapha Taha, Veronica Venturelli, Andrea Lo Monaco, Marcello Govoni

    Published 2025-01-01
    “…Over the past few years, Janus kinase inhibitors (JAKis) have been reported to have promising efficacy in the treatment of active RA, but recent concerns have been raised about their safety profile, namely malignancy and cardiovascular disease, limiting their use to certain patient categories. …”
    Get full text
    Article
  18. 618

    Involvement of different protein kinases and phospholipases A2 in phorbol ester (TPA)-induced arachidonic acid liberation in bovine platelets by M. Lehr, K. Griessbach

    Published 2000-01-01
    “…The effect of various phospholipase A2 and protein kinase inhibitors on the arachidonic acid liberation in bovine platelets induced by the protein kinase activator 12-O-tetradecanoylphorbol–13-acetate (TPA) was studied. …”
    Get full text
    Article
  19. 619

    Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma by Yuxuan Song, Yiqing Du, Shan Jiang, Yun Peng, Xing Luo, Tao Xu

    Published 2025-01-01
    “…Selective pan-FGFR tyrosine kinase inhibitor (FGFRi) has been approved for FGFR-altered UC. …”
    Get full text
    Article
  20. 620

    Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder by Syouichi Katayama, Noriyuki Sueyoshi, Tetsuya Inazu, Isamu Kameshita

    Published 2020-01-01
    “…Cyclin-dependent kinase-like 5 (CDKL5, also known as STK9) is a serine/threonine protein kinase originally identified in 1998 during a transcriptional mapping project of the human X chromosome. …”
    Get full text
    Article